AVE 0675

Drug Profile

AVE 0675

Alternative Names: AVE0675

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Coley Pharmaceutical Group
  • Developer Coley Pharmaceutical GmbH; sanofi-aventis
  • Class Antiasthmatics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 01 Jan 2008 Coley Pharmaceutical Group has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top